# POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

> **NCT04690322** · PHASE4 · WITHDRAWN · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Hemophilia A
- Factor VIII

## Interventions

- **DRUG:** Eloctate
- **DRUG:** Adynovate
- **DRUG:** Emicizumab

## Key facts

- **NCT ID:** NCT04690322
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-04-15
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to COVID-19 pandemic, recruitment was temporarily put on hold. We are withdrawing this registration due to a recent amendment to the protocol that includes major changes to data elements. A new registration will be submitted for the new protocol.
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04690322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04690322, "POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04690322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*